10.03.2016
AquaDerma wins Norwegian cosmetic award 2016
AquaDerma, the new LEX® containing cosmetic series from Orkla Lilleborg wins Norwegian Cosmetics Award 2016. 
10.02.2016
Eurostars consortium established
Eurostars consortium established by Regenics AS, Norway
24.11.2015
DnB Healthcare conference 2015
Regenics AS presents at the DnB Healtcare conference 2015, Venture session, December 15th 2015, session 5 at 15:39 Welcome!
08.11.2015
In-cosmetics Bangkok 2015
In Cosmetics, 2015, Bangkok  
21.10.2015
Faster reepitelialization in burn wounds ETRS-WHS abstract
Regenics today annonces a positive result for its wound healing technology using salmon roe extracts to treat 2nd degree burn wounds in human skin
10.07.2015
Asia and Australia Distributors for LEX®
Regenics AS has signed non-exclusive test sale agreements for LEX® with selected cosmetic ingredient distributors for China, Taiwan, Korea and Australia.  
18.05.2015
Regenics Joins Oslo Cancer Cluster
Regenics was May 18th invited as a member  of Oslo Cancer Cluster NCE (Norwegian Centre for Expertise). 
30.04.2015
Medibiome AB preliminary report
Medibiome AB issues today a preliminary report of first results of Vernex™ exposure to human skin explants showing improved and faster reepitelialization of seconday degree induced burn wounds over placebo.
17.04.2015
In-cosmetics Barcelona 2015
Regenics visited in-cosmetics in Spain, which held on 14-16th April. Participation in the largest cosmetics fairs in Europe was for Regenics great opportunity to meet with current customers and establish...
16.04.2015
BIA 2015 grant to Regenics AS
Regenics receieves 2015-2018 R&D grant from Norwegian Research Council in the BIA (brukerstyrt innovasjonsarena) programme.
02.04.2015
Regenics AS Annual Report 2014
Regenics AS Annual Report 2014
11.03.2015
2015 Eurostars funding to Regenics
Regenics is awarded Eurostars R&D funding for Vernex® wound healing device development.
25.02.2015
Medibiome AB collaboration
Medibiome AB, Sweden and Regenics AS Oslo agrees collaboration on evaluation of Vernex™ in human skin explant model.
08.02.2015
Orkla-Lilleborg launches AquaDerma
Lilleborg launches AquaDerma - a new, LEX® containing cosmetic series in Norway.
13.01.2015
LEX® trademark issued in US
The trademark LEX® for salmon roe extract used for cosmetic purposes has today been approved by US Patent Office 
01.01.2015
Dominika Andrys joins Regenics
Dominika Andrys joins Regenics

<<  <   Page 4 of 5   >  >>

REGENICS AT EVENTS

June 5-6th 2017

Investor Conference Biotech-Medtech, at Stavanger Forum Oslo

Program (tbd)

March 9th 2017

Roundtable Conference in investing in Biotech, CEO Henrik Lund, moderator for the Event at Stavanger Forum Oslo

Program Roundtable Conference Stavanger

March 8th 2017

War on Cancer Nordics, CEO Henrik Lund participating in closing panel at the Economist Event in Oslo

Program Economist Event Oslo

December 15th 2016

DnB Healtcare Conference 2016, CMO Christian Clemm provides company update in the ventture session

Regenics presentation   

October 19-20-21 2016

Biomarine Convention, CEO Henrik Lund, participating at Convention in Oslo

Program Biomarine Business Conference

October 19th 2016

DnB Next at Oslo Innovation Week, CSO Gry Lønne, presenting Regenics Company update in Oslo

program DNB Next healthcare      Regenics presentation 

September 25-28 2016

At the 4th Congress on Innovation in Drug Delivery in Antibes, Regenics publish data on its carrier/vehicle GMO to be used in the CE marking device for wound healing.

Abstract 4th Congress on Innovation in Drug Delivery

October 22-24 2015

At the Joint Meeting of the European Tissue Repair Society (ETRS) and the Wound Healing Society (WHS), Regenics showed excellent and rapid wound healing of its wound healing device Vernex under development for CE-marking in 2018. In 2nd degree burn wounds Vernex provided rapid and complete reepitelialization of epidemal keratinocytes in human explanted skin. This represent a prooof of priciple for the utility of Vernex in human wound healing. 

Abstract 7th ETRS-WHS meeting

Regenics AS has developed a number of assays and techniques to study effects of various substances on skin cells both in vitroin vivo and in the clinic. Our focus is to develop products and techniques for therapeutic skin applications and to improve skin appearance.